Synthetic oligonucleotides recruit ILF2/3 to RNA transcripts to modulate splicing

Nature Chemical Biology

Volumn 8, Issue 6, 2012, Pages 555-561

  Rigo, Frank ^a   Hua, Yimin ^b   Chun, Seung J ^a   Prakash, Thazha P ^a   Krainer, Adrian R ^b   Bennett, C Frank ^a  

^a ISIS PHARMACEUTICALS   (United States)

^b Cold Spring Harbor Llaboratory ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' DEOXY 2' FLUORO ANTISENSE OLIGONUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; INTERLEUKIN ENHANCER BINDING FACTOR 2; INTERLEUKIN ENHANCER BINDING FACTOR 3; MESSENGER RNA; MESSENGER RNA PRECURSOR; SINGLE STRANDED RNA; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ANIMAL EXPERIMENT; CELL CULTURE; CHEMICAL COMPOSITION; CHEMICAL MODIFICATION; CONTROLLED STUDY; EXON; EXON SKIPPING; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN RNA BINDING; REVIEW; RNA TRANSCRIPTION;

MUS;

EID: 84861326886     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.939     Document Type: Review

References (47)

1. Glisovic, T., Bachorik, J.L., Yong, J. & Dreyfuss, G. RNA-binding proteins and post-transcriptional gene regulation. FEBS Lett. 582, 1977-1986 (2008).
2. Licatalosi, D.D. & Darnell, R.B. RNA processing and its regulation: global insights into biological networks. Nat. Rev. Genet. 11, 75-87 (2010).
3. Calarco, J.A., Zhen, M. & Blencowe, B.J. Networking in a global world: establishing functional connections between neural splicing regulators and their target transcripts. RNA 17, 775-791 (2011).
4. Cooper, T.A., Wan, L. & Dreyfuss, G. RNA and disease. Cell 136, 777-793 (2009).
5. Lunde, B.M., Moore, C. & Varani, G. RNA-binding proteins: modular design for efficient function. Nat. Rev. Mol. Cell Biol. 8, 479-490 (2007). (Pubitemid 46809150)
6. Auweter, S.D., Oberstrass, F.C. & Allain, F.H. Sequence-specific binding of single-stranded RNA: is there a code for recognition? Nucleic Acids Res. 34, 4943-4959 (2006). (Pubitemid 44605637)
7. Tian, B., Bevilacqua, P.C., Diegelman-Parente, A. & Mathews, M.B. The double-stranded-RNA-binding motif: interference and much more. Nat. Rev. Mol. Cell Biol. 5, 1013-1023 (2004). (Pubitemid 39611537)
8. Wahl, M.C., Will, C.L. & Luhrmann, R. The spliceosome: design principles of a dynamic RNP machine. Cell 136, 701-718 (2009).
9. Wang, Y., Cheong, C.G., Hall, T.M. & Wang, Z. Engineering splicing factors with designed specificities. Nat. Methods 6, 825-830 (2009).
10. Mackay, J.P., Font, J. & Segal, D.J. The prospects for designer single-stranded RNA-binding proteins. Nat. Struct. Mol. Biol. 18, 256-261 (2011).
11. Culler, S.J., Hoff, K.G. & Smolke, C.D. Reprogramming cellular behavior with RNA controllers responsive to endogenous proteins. Science 330, 1251-1255 (2010).
12. Baughan, T.D., Dickson, A., Osman, E.Y. & Lorson, C.L. Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy. Hum. Mol. Genet. 18, 1600-1611 (2009).
13. Cartegni, L. & Krainer, A.R. Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat. Struct. Biol. 10, 120-125 (2003). (Pubitemid 36177092)
14. Skordis, L.A., Dunckley, M.G., Yue, B., Eperon, I.C. & Muntoni, F. Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc. Natl. Acad. Sci. USA 100, 4114-4119 (2003). (Pubitemid 36418166)
15. Villemaire, J., Dion, I., Elela, S.A. & Chabot, B. Reprogramming alternative pre-messenger RNA splicing through the use of protein-binding antisense oligonucleotides. J. Biol. Chem. 278, 50031-50039 (2003). (Pubitemid 37548839)
16. Goraczniak, R., Behlke, M.A. & Gunderson, S.I. Gene silencing by synthetic U1 adaptors. Nat. Biotechnol. 27, 257-263 (2009).
17. Bennett, C.F. & Swayze, E.E. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol. 50, 259-293 (2010).
18. Bauman, J., Jearawiriyapaisarn, N. & Kole, R. Therapeutic potential of splice-switching oligonucleotides. Oligonucleotides 19, 1-13 (2009).
19. Bennett, C.F. et al. Antisense oligonucleotide-based therapeutics. in Gene and Cell Therapy: Therapeutic Mechanisms and Strategies (ed. Templeton, N.S.) 497-522 (Taylor & Francis Group, 2009).
20. Swayze, E.E. & Balkrishen, B. The medicinal chemistry of oligonucleotides. in Antisense Drug Technology: Principles, Strategies and Applications (ed. Crooke, S.T.) 143-182 (Taylor & Francis Group, 2008).
21. Seth, P.P. et al. Synthesis and biophysical evaluation of 2′,4′-constrained 2′O-methoxyethyl and 2′,4′- constrained 2′O-ethyl nucleic acid analogues. J. Org. Chem. 75, 1569-1581 (2010).
22. Levin, A.A., Yu, R.Z. & Geary, R.S. Basic principles of the pharmacokinetics of antisense oligonucleotide drugs. in Antisense Drug Technology: Principles, Strategies and Applications (ed. Crooke, S.T.) 183-215 (Taylor & Francis Group, 2008).
23. Chen, M. & Manley, J.L. Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat. Rev. Mol. Cell Biol. 10, 741-754 (2009).
24. Hua, Y., Vickers, T.A., Okunola, H.L., Bennett, C.F. & Krainer, A.R. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am. J. Hum. Genet. 82, 834-848 (2008).
25. Lorson, C.L., Hahnen, E., Androphy, E.J. & Wirth, B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl. Acad. Sci. USA 96, 6307-6311 (1999). (Pubitemid 29256661)
26. Pandya-Jones, A. & Black, D.L. Co-transcriptional splicing of constitutive and alternative exons. RNA 15, 1896-1908 (2009).
27. Noguchi, T., Inoue, H. & Tanaka, T. The M1-and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing. J. Biol. Chem. 261, 13807-13812 (1986). (Pubitemid 17196407)
28. Christofk, H.R. et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230-233 (2008). (Pubitemid 351380249)
29. Boise, L.H. et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74, 597-608 (1993). (Pubitemid 23259741)
30. Goedert, M., Spillantini, M.G., Potier, M.C., Ulrich, J. & Crowther, R.A. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J. 8, 393-399 (1989). (Pubitemid 19274956)
31. Rademakers, R., Cruts, M. & van Broeckhoven, C. The role of tau (MAPT) in frontotemporal dementia and related tauopathies. Hum. Mutat. 24, 277-295 (2004). (Pubitemid 39336634)
32. Singh, N.K., Singh, N.N., Androphy, E.J. & Singh, R.N. Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol. Cell. Biol. 26, 1333-1346 (2006). (Pubitemid 43202560)
33. Guan, D. et al. Nuclear factor 45 (NF45) is a regulatory subunit of complexes with NF90/110 involved in mitotic control. Mol. Cell. Biol. 28, 4629-4641 (2008). (Pubitemid 351977760)
34. Liao, H.J., Kobayashi, R. & Mathews, M.B. Activities of adenovirus virus-associated RNAs: purification and characterization of RNA binding proteins. Proc. Natl. Acad. Sci. USA 95, 8514-8519 (1998). (Pubitemid 28350519)
35. Kawasaki, A.M. et al. Uniformly modified 2′-deoxy-2′-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets. J. Med. Chem. 36, 831-841 (1993). (Pubitemid 23118776)
36. Teplova, M. et al. Crystal structure and improved antisense properties of 2′-O-(2-methoxyethyl)-RNA. Nat. Struct. Biol. 6, 535-539 (1999). (Pubitemid 29252831)
37. Li, F. et al. 2′-Fluoroarabino-and arabinonucleic acid show different conformations, resulting in deviating RNA affinities and processing of their heteroduplexes with RNA by RNase H. Biochemistry 45, 4141-4152 (2006).
38. Inoue, H. et al. Synthesis and hybridization studies on two complementary nona(2′-O-methyl)ribonucleotides. Nucleic Acids Res. 15, 6131-6148 (1987).
39. Wilds, C.J. & Damha, M.J. 2′-Deoxy-2′-fluoro-β-D- arabinonucleosides and oligonucleotides (2′F-ANA): synthesis and physicochemical studies. Nucleic Acids Res. 28, 3625-3635 (2000).
40. Vester, B. & Wengel, J. LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA. Biochemistry 43, 13233-13241 (2004). (Pubitemid 39391124)
41. Jepsen, J.S., Sorensen, M.D. & Wengel, J. Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology. Oligonucleotides 14, 130-146 (2004). (Pubitemid 38987382)
42. Liu, J., Hu, J. & Corey, D.R. Expanding the action of duplex RNAs into the nucleus: redirecting alternative splicing. Nucleic Acids Res. 40, 1240-1250 (2011).
43. Cohen, J.S. Informational drugs: a new concept in pharmacology. Antisense Res. Dev. 1, 191-193 (1991).
44. Wang, G.S. & Cooper, T.A. Splicing in disease: disruption of the splicing code and the decoding machinery. Nat. Rev. Genet. 8, 749-761 (2007). (Pubitemid 47429207)
45. Barber, G.N. The NFAR's (nuclear factors associated with dsRNA): evolutionarily conserved members of the dsRNA binding protein family. RNA Biol. 6, 35-39 (2009).
46. Win, M.N., Liang, J.C. & Smolke, C.D. Frameworks for programming biological function through RNA parts and devices. Chem. Biol. 16, 298-310 (2009).
47. Hua, Y. et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 24, 1634-1644 (2010).